Pharming Group N.V. today announced that it has issued a total of 25,441,901 new shares and €1.9 million of cash to redeem €7.7 million of the Ordinary Convertible Bonds (“Bonds”).

Pharming Group N.V. today announced that it has issued a total of 10,563,380 new shares from within the amount allocated to conversion of the Ordinary Convertible Bonds (the “Bonds”) to redeem €3.0 million of the Bonds being converted by their holders, thereby reducing the outstanding amount of the Bonds to €8.5 million.

Pharming Group N.V., the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.

Pharming Group N.V. today announced that since the release of its update regarding cashless and other warrant exercises and bond conversions on 10 August 2017, it has issued 12,548,663 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.

Pharming Group N.V. today announced that since the release of its 2017 Half Year Report on 27 July 2017, it has issued 12,053,268 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2017.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. today announced that the supervisory board and the management board have jointly decided to withdraw the agenda items related to the Amendment of Pharming’s Articles of Association from the agenda of the AGM scheduled for Wednesday, 24 May 2017 at 14:00 hours.

Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2017.

Pharming Group N.V. announces that it has completed a new US$100 million finance agreement with Orbimed Advisors.